ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 6-month report/LifeWatch AG 19.07.2010 - 07:00 a.m. CEST: Press release/Letter to Shareholders; - 10:00 a.m. CEST: Analyst/Media Conference; ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/Disclosure of equity participations 08.07.2010 Henderson Global Investors take significant stake in LifeWatch AG Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 6-month report/LifeWatch AG 01.07.2010 - Press release at 7:00 a.m. CEST. - Analyst and media conference held in Zurich at 10:00 a.m. CEST. - International Live Conference Call/Web cast at 10:00 a.m. ...
Freising-Weihenstephan (ots) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive expertise in therapeutic protein drug development. "Laurent has an impressive track record of leading teams and ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/LifeWatch AG 26.05.2010 Shareholders approve all proposals of the Board of Directors Gregory Henry Volkart, Dr. Abraham Sartani and Urs Wettstein re-elected as members of the Board for a one-year term of office National ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. New Products/LifeWatch AG 11.05.2010 Chicago, IL / USA May 11 2010 -LifeWatch Services, Inc., a subsidiary of LifeWatch AG (SIX Swiss Exchange: LIFE), will announce the launch of their remote ECG ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. New Products/LifeWatch AG 11.05.2010 First in Series of Treatment-Specific Remote Patient Monitoring Services Chicago, IL / USA May 11 2010 - LifeWatch Services, Inc., a subsidiary of LifeWatch AG (SIX Swiss Exchange: LIFE), will unveil its advanced ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/LifeWatch AG 11.05.2010 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote cardiac and medical patient monitoring service ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report/LifeWatch AG Q1 2010 11.05.2010 Ongoing positive cash flow ACT patient enrollments up 37% to 21,099 patients The first 300 patient enrollments for the NiteWatch service Additions of managers with proven track record to LifeWatch ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report/LifeWatch AG 03.05.2010 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote ...
Freising-Weihenstephan (ots) - Novel Approach with PRS-110 Shows Dose-dependent Response in Cancer Model Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin" compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model. The results provide an indication that an ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report/LifeWatch AG 21.04.2010 - Press release at 7:00 a.m. CEST - Analyst and media conference held in Zurich at 09:30 a.m. CEST - International Live Conference Call/Webcast at 09:30 a.m. ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. annual report/LifeWatch AG 19.04.2010 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE) today published its Annual Report 2009 including results for the financial year 2009 as presented on February 24, 2010. The LifeWatch ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information 15.04.2010 Neuhausen am Rheinfall / Switzerland, April 15, 2010 - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading ...
Zürich (ots) - Solianis Monitoring AG is an important project partner in the development of REACTION, a professional service platform for doctors, caregivers and patients to improve the long term management of diabetes. The objective of the project is to improve glucose control in insulin requiring ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 24.02.2010 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading provider of wireless cardiac monitoring ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. annual report 05.02.2010 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE) announces its results for the full fiscal ...
Tokyo, Japan and Edison, N.J. (ots) - First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 11.01.2010 Neuhausen am Rheinfall / Switzerland, January 11, 2010 - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote cardiac and ...
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...
Zug (ots) - The Swiss biopharmaceuticals company AmVac AG in Zug has joined forces with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private equity company based in Dresden has invested CHF 1,500,000 in AmVac AG since the first half of 2009. Last week V+ GmbH & Co Fonds 2 KG announced their intention of acquiring further shares in AmVac AG to the sum of CHF 3,000,000.00. Michael Vogel, spokesman of the investment board: "We agree with boosting ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. New Products/NiteWatch Accreditation 23.11.2009 Neuhausen am Rheinfall / Switzerland, November 23, 2009 - LifeWatch AG (SIX Swiss Exchange: LIFE), ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information/Disclosure of Equity Participations 12.11.2009 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE) announced today that according to a notification ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report/LifeWatch Financial Results Q3 2009 05.11.2009 Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE), the ...
- Press release at 7:00 a.m. CET - Analyst and media conference held in Zurich at 09:30 a.m. CET Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. quarterly report/Invitation analysts conference Subtitle: - Press release at 7:00 a.m. ...
The International Osteoporosis Foundation (IOF)
Rome, Italy (ots) - Speaking in Rome, Italy today on the occasion of World Osteoporosis Day, International Osteoporosis Foundation (IOF) CEO Patrice McKenney called for individuals and governments around the globe to join the fight against osteoporosis. "Osteoporosis is a common but devastating disease which we cannot afford to ignore. Immediate measures must ...
The International Osteoporosis Foundation (IOF)
Nyon (ots) - The International Osteoporosis Foundation (IOF) will issue a new 16- page report on FRAX® to mark World Osteoporosis Day. The report is available at www.iofbonehealth.org . FRAX®, or 'WHO Fracture Risk Assessment Tool', is a free online tool developed by the World Health Organization at http://www.shef.ac.uk/FRAX/ . The tool helps clinicians identify people who are most in need of treatment ...
- Press release at 7:00 a.m. CET - Analyst and media conference held in Zurich at 09:30 a.m. CET Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. 3-month report/Invitation analysts conference Utl.: - Press release at 7:00 a.m. CET - Analyst and media conference held in Zurich at 09:30 ...
Zurich (ots) - - Indication: Health Tips from EAACI can be downloaded free of charge as a pdf-file under: http://www.presseportal.ch/de/pm/100018272/?langid=2 - EAACI, the largest European organisation in the field of allergy, immunology and asthma, today hosted a specialist forum on "Swine-flu - a threat for asthmatics? What people ...
Lugano/Berlin, Germany (ots) - Single dose palonosetron achieves optimal control of acute emesis in patients receiving multiday-high dose chemotherapy before autologous stem cell transplantation. The addition of a second dose of palonosetron after 48 hours significantly reduces the detrimental impact of ...